Demographic trends and disease‐specific survival in salivary acinic cell carcinoma: An analysis of 1129 cases

Abstract

Trends in incidence of AciCC are influenced by gender, race and age. Long-term survival of this rare malignant tumor is influenced by gender, grade, race, and extent of disease. Future studies need to be conducted to investigate these dynamic trends related to AciCC.

Salivary Gland Cancers: A Survey through History, Classifications and Managements

“…Based on 1973-2009 Surveillance, Epidemiology, and End Results (SEER) analysis AcCC comprises 11% of salivary malignancies [24]. AcCC has an average annual incidence of 0.13 cases per 100,000 patients per year.…”

“…Patients with AcCC have a median age of 52 years at the time of diagnosis and it occurs more in younger ages than other salivary gland tumors [27]. One-third of patients are under 40, one-third between 40 and 59 and one-third above 60 years of age [24]. AcCC more frequently occurs in whites (85%) than in blacks (7%) or other races (8%) [24,28].…”

“…One-third of patients are under 40, one-third between 40 and 59 and one-third above 60 years of age [24]. AcCC more frequently occurs in whites (85%) than in blacks (7%) or other races (8%) [24,28]. There are no known risk factors for AcCC; however, family history and radiation exposure have been proposed as potential risk factors [29].…”

“…As like other salivary gland cancers, criteria for radiotherapy include recurrent disease, advanced T-classiication (T3/T4), positive margins, pathologically positive cervical lymph nodes, perineural invasion, high-grade and high proliferative tumors [24,26,28].…”

World Health Organization 4th edition of head and neck tumor classification: insight into the consequential modifications

“…In the past, the lack of firm features to classify these tumors has led to empirically include them with acinic carcinoma as the most closely related phenotype [18,19]. Nowadays, a sufficient number of publications have detailed the morphologic features, immunohistochemical markers, and the molecular identification of the ETV6-NTRK-3 fusion in multiple variable techniques, justifying its recognition as a new entity [20,21].…”